Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.
BeyondSpring (NASDAQ:BYSI) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Plinabulin in combination with docetaxel for previously treated advanced non-squamous lung cancer.
Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.
Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.
Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.
Unicycive Therapeutics (NASDAQ:UNCY) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in patients receiving dialysis.
uniQure (NASDAQ:QURE) reported additional Phase I/II data for ifezuntirgene inilparvovec, its investigational gene therapy for Huntington’s disease, with follow-up results extending to 36 and 48 months.
Invivyd (NASDAQ:IVVD) reported Phase 3 LIBERTY trial results showing that its investigational COVID-19 antibody product VYD2311 demonstrated fewer reported adverse events compared with an mRNA COVID-19 vaccine.
IM Cannabis (NASDAQ:IMCC) completed the sale of IMC Holdings to Slil, following a transaction that included a previously paid C$3 million payment as part of the consideration.
Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Zepbound 10 mg and 15 mg were associated with greater weight loss than Wegovy HD 7.2 mg in adults with obesity.
Kura Oncology (NASDAQ:KURA) and Caspian Therapeutics presented preclinical findings for KO-7246, an investigational diabetes treatment candidate, at the European Association for the Study of Diabetes (EASD) meeting in Milan.
Jaguar Health (NASDAQ:JAGX) announced that an abstract covering preliminary results from an adult short bowel syndrome study has been accepted for presentation at the American College of Gastroenterology (ACG) 2026 meeting.
